Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults

Archives of Internal Medicine

Volumn 148, Issue 1, 1988, Pages 36-69

 

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CLOFIBRATE; COLESTIPOL; COLESTYRAMINE; GEMFIBROZIL; LOW DENSITY LIPOPROTEIN; MEVINOLIN; NICOTINIC ACID; PROBUCOL;

ARTERIOSCLEROSIS; CORONARY ARTERY DISEASE; DIET; HUMAN; HYPERCHOLESTEROLEMIA; REVIEW;

ADULT; AGED; CHOLESTEROL; CHOLESTYRAMINE; COLESTIPOL; CORONARY DISEASE; DIETARY FATS; FEMALE; GEMFIBROZIL; HUMAN; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYPERCHOLESTEROLEMIA; LIPOPROTEINS, LDL CHOLESTEROL; MALE; MIDDLE AGE; NIACIN; PATIENT COMPLIANCE; PENTANOIC ACIDS; PROBUCOL; RISK FACTORS;

EID: 0023930868     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.1988.00380010040006     Document Type: Article

References (60)

1. 1. Consensus Development Conference: Lowering blood cholesterol to prevent heart disease. JAMA 1985;253:2080-2086.
2. 2. Atherosclerosis Study Group: Optimal resources for primary prevention of atherosclerotic diseases. Circulation 1984;70:157A-205A.
3. 3. Grundy SM: Cholesterol and coronary heart disease: A new era. JAMA 1986;256:2849-2858.
4. 4. Hulley SB, Rhodes GG: The plasma lipoproteins as risk factors: Comparison of electrophoretic and ultracentrifugation results. Metabolism 1982;31:773-777.
5. 5. Martin MJ, Hulley SB, Browner WS, et al: Serum cholesterol, blood pressure, and mortality: Implications from a cohort of 361662 men. Lancet 1986;2:933-936.
6. 6. Stamler J, Wentworth D, Neaton J: Is the relationship between serum cholesterol and risk of death from CHD continuous and graded? JAMA 1986;256:2823-2828.
7. 7. Schaefer EJ, Levy RI: Pathogenesis and management of lipoprotein disorders. N Engl J Med 1985;312:1300-1310.
8. 8. Brown NS, Goldstein JL: A receptor-mediated pathway for cholesterol homeostasis. Science 1986;232:34-47.
9. 9. Ross R: The pathogenesis of atherosclerosis—an update. N Engl J Med 1986;314:488-500.
10. 10. Lipid Research Clinics Program: The Lipid Research Clinics Coronary Primary Prevention Trial results: I. Reduction in the incidence of coronary heart disease. JAMA 1984;251:351-364.
11. 11. Canner PL, Berge KG, Wenger NK, et al: Fifteen-year mortality in Coronary Drug Project patients: Long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245-1255.
12. 12. Blankenhorn DM, Nessim SA, Johnson RL, et al: Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987;257:3233-3240.
13. 13. Lipid Research Clinics Program: The Lipid Research Clinics Coronary Primary Prevention Trial results: II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984;251:365-374.
14. 14. Kannel WB, Neaton JD, Wentworth D, et al: Overall and CHD mortality rates in relation to major risk factors in 325 348 men screened for the MRFIT. Am Heart J 1986;112:825-836.
15. 15. Study Group, European Atherosclerosis Society: Strategies for the prevention of coronary heart disease: A policy statement of the European Atherosclerosis Society. Eur Heart J 1987;8:77-88.
16. 16. Jacobs D, Barrett-Conner E: Re-test reliability of plasma cholesterol and triglycerides: The Lipid Research Clinics Prevalence Study. Am J Epidemiol 1982;116:878-885.
17. 17. Koke JD, Hawkins DL: Estimating baseline values of the variables of intervention in a clinical trial. Contr Clin Trials 1985;6:136-145.
18. 18. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
19. 19. DeLong DM, DeLong ER, Wood PD, et al: A comparison of methods for the estimation of plasma low- and very-low-density lipoprotein cholesterol: The Lipid Research Clinics Prevalence Study. JAMA 1986;256:2372-2377.
20. 20. Goldstein JL, Schrott HG, Hazzard WR, et al: Hyperlipidemia in coronary heart disease: II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 1973;52:1544-1568.
21. 21. Castelli WP: The triglyceride issue: A view from Framingham. Am Heart J 1986;112:432-437.
22. 22. Consensus Development Conference: Treatment of hypertriglyceridemia. JAMA 1984;251:1196-1200.
23. 23. National Center for Health Statistics: Total serum cholesterol levels of adults 20 to 74 years of age: United States, 1976-1980, Vital and Health Statistics, Ser. II, No. 236. Dept Health and Human Services publication (PHS) 86-1686. Government Printing Office, May 1986.
24. 24. Lerner DJ, Kanner WB: Patterns of coronary heart disease morbidity and mortality in the sexes: A 26-year follow-up of the Framingham population. Am Heart J 1986;111:383-390.
25. 25. Feinlieb M, Gillum RF: CHD in the elderly: The magnitude of the problem in the US, in Wenger NK, Furberg CD, Pitt E (eds): CHD in the Elderly. New York, Elsevier, 1986, pp 29-59.
26. 26. Grundy SM, Bilheimer D, Blackburn H, et al: Rationale of the diet-heart statement of the American Heart Association: Report of Nutrition Committee. Circulation 1982;65:839A-854A.
27. 27. Stamler J: Population studies, in Levy RI, Rifkind BM, Dennis BH, et al (eds): Nutrition, Lipids, and Coronary Diseases: A Global View. New York, Raven Press, 1979, pp 25-88.
28. 28. Hjermann I, Velve Byre K, Holme I, et al: Effect of diet and smoking intervention on the incidence of coronary heart disease. Lancet 1981;2:1303-1310.
29. 29. Gotto AM Jr, Bierman EL, Connor WE, et al: Recommendations for treatment of hyperlipidemia in adults: A joint statement of the Nutrition Committee and the Council on Arteriosclerosis. Circulation 1984;69:1067A-1090A.
30. 30. Keys A, Anderson JT, Grande F: Serum cholesterol response to changes in the diet. Metabolism 1965;14:747-787.
31. 31. Hegsted DM, McGandy RB, Myers ML, et al: Quantitative effects of dietary fat on serum cholesterol in man. Am J Clin Nutr 1965;17:281-295.
32. 32. Keys A, Grande F, Anderson JT: Bias and misrepresentation revisited: Perspective on saturated fat. Am J Clin Nutr 1974;27:188-212.
33. 33. Keys A (ed): Coronary heart disease in seven countries. Circulation 1970;41(suppl 1):I-1-I-211.
34. 34. Herold PM, Kinsella JE: Fish oil consumption and decreased risk of cardiovascular disease: A comparison of findings from animal and human feeding trials. Am J Clin Nutr 1986;43:566-598.
35. 35. Mattson FH, Erickson BA, Kligman AM: Effect of dietary cholesterol on serum cholesterol in man. Am J Clin Nutr 1972;25:589-594.
36. 36. Ginsberg H, Le NA, Mays C, et al: Lipoprotein metabolism in nonresponders to increased dietary cholesterol. Arteriosclerosis 1981;1:463-470.
37. 37. Keys A: Serum cholesterol response to dietary cholesterol. Am J Clin Nutr 1984;40:351-359.
38. 38. Schonfeld G, Patsch W, Rudell LL, et al: Effects of dietary cholesterol and fatty acids on plasma lipoproteins. Am J Clin Invest 1982;69:1072-1080.
39. 39. Anderson LW, Story L, Sieling B, et al: Hypocholesterolemic effects of oat-bran or bean intake for hypercholesterolemic men. Am J Clin Nutr 1984;40:1146-1155.
40. 40. Harlan WR, Hull AL, Schmouder RL, et al: Blood pressure and nutrition in adults: The National Health and Nutrition Examination Survey. Am J Epidemiol 1984;120:17-28.
41. 41. Hennekens CH: Alcohol, in Kaplan NM, Stamler J (eds): Prevention of Coronary Heart Disease. Philadelphia, WB Saunders Co, 1983, pp 130-138.
42. 42. Hubert HB, Feinlieb M, McNamara PM, et al: Obesity as an independent risk factor for cardiovascular disease: A 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983;67:968-977.
43. 43. Shekelle RB, Shryock AM, Paul O, et al: Diet, serum cholesterol, and death from coronary heart disease—The Western Electric Study. N Engl J Med 1981;304:65-70.
44. 44. Kromhout D, Bosschieter EB, Coulander CdeL: The inverse reaction between fish consumption and 20-year mortality from coronary heart disease. N Engl J Med 1985;312:1205-1209.
45. 45. American Heart Association: Dietary guidelines for healthy American adults: A statement for physicians and health professionals by the Nutrition Committee, American Heart Association. Circulation 1986;74:1465A-1468A.
46. 46. Raab C, Tillotson JL (eds): Heart to Heart: A Manual on Nutrition Counseling for the Reduction of Cardiovascular Disease Risk Factors. National Institutes of Health Publication No. 83-1528.
47. 47. US Dept Agriculture and Dept Health and Human Services: Nutrition and Your Health: Dietary Guidelines for Americans, ed 2. US Dept Agriculture Home and Garden Bulletin, No. 232, 1985.
48. 48. Pennington J, Church H: Bowes and Church’s Food Values of Portions Commonly Used, ed 14. Philadelphia, JB Lippincott, 1985.
49. 49. US Dept Agriculture: Nutritive Value of Foods. US Dept Agriculture Home and Garden Bulletin, No. 72, 1986.
50. 50. Brown WV, Goldberg IJ, Ginsberg HN: Treatment of common lipoprotein disorders. Progr Cardiovasc Dis 1984;27:1-21.
51. 51. Hoeg JM, Gregg RE, Brewer HB Jr: An approach to the management of hypercholesterolemia. JAMA 1986;255:512-521.
52. 52. Illingworth DR: Lipid-lowering drugs: An overview of indication and optimum therapeutic use. Drugs 1987;33:259-279.
53. 53. Coronary Drug Project Research Group: Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360-381.
54. 54. Knopp RH, Ginsberg J, Albers JJ, et al: Contrasting effects of unmodified and time-released forms of niacin on lipoproteins in hyperlipidemic subjects: Clues to mechanism of action of niacin. Metabolism 1985;34:642-647.
55. 55. Lovastatin Study Group II: Therapeutic response to lovastatin (mevinolin) in nonfamilial hypercholesterolemia: A multicenter trial. JAMA 1986;256:2829-2834.
56. 56. Illingworth DR: Mevinolin (lovastatin) plus colestipol in therapy for severe heterozygous familial hypercholesterolemia. Ann Intern Med 1984;101:598-604.
57. 57. Steinberg D: Studies on the mechanism of action of probucol. Am J Cardiol 1986;57:16H-21H.
58. 58. Committee of Principal Investigators, World Health Organization Clofibrate Trial: A cooperative trial in the primary prevention of ischemic heart disease using clofibrate. Br Heart J 1978;40:1069-1118.
59. 59. Helsinki Heart Study Ethical Committee: Safety as a factor in lipid-regulating primary prevention drug trials: The Helsinki Heart Study Interim Report: Royal Society of Medicine Services. Int Congr Symp Senes 1986;87:51-61.
60. 60. Kane JP, Malloy MJ, Tun P, et al: Normalization of low-density lipoprotein levels in heterozygous familial hypercholesterolemia with a combined drug regimen. N Engl J Med 1981;304:251-258.